Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509179-18-00

Acronym

C2321001

Enrollment

106

Registered

2024-08-28

Start date

2019-08-13

Completion date

Unknown

Last updated

2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026